First-in-Class GI Cancer Therapies.
Transforming Tomorrow's Care Today.
Why focus on Gastro-Intestinal Cancer?
The magic behind
YB-800
Check out our latest video that shows the fluorescence immune histochemistry with YB-800 on human gastric cancer tissue.
YB-800
​Our research into a new target receptor in oncology is focused on its development as a first-in-class ADC (antibody drug conjugate) target in GI cancers. Our fully humanized antibody binds to tumor cells selectively, and healthy tissue is not affected.
The new target receptor was discovered through analyses of a large tumor bank.
ADC development work is currently ongoing.
Ymmunobio is in pre-clinical development focusing on GI cancers mainly with their platform supporting:
​
ADC: YB-800ADC1 with 3rd generation linker carrying 8 tubulin inhibitors: indications in Solid Tumors
ADC: YB-800ADC2 with 3rd generation linker carrying 4 tubulin inhibitors and 4 topoisomerase inhibitors:
indications in Solid Tumors
Radiopharmaceutical: YB-800R1 carrying 177Lutetium: Indications in Solid Tumors
Radiopharmaceutical: YB-800R2 carrying 161Terbium: Indications in Solid tumors
Radiopharmaceutical: YB-800D for SPECT Imaging diagnostic purposes
Bi-specific mAb: YB-800BS1 featuring an aCD3 component
Bi-specific mAb: YB-800BS2 featuring an aCD3 component
YB-800 Development Timelines
